Figure 3.

Overall survival (OS) at 12‐week landmark. The Kaplan‐Meier method was performed to evaluate OS based on response status at 12 weeks after the start of pazopanib treatment. Clinical benefit was defined as patients having SD, PR (>30% reduction in tumor size), or CR by Response Evaluation Criteria In Solid Tumors 1.1 criteria. No response was defined as patients having PD (>20% growth in tumor size).

Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.